TITLE

THEN & NOW

AUTHOR(S)
Widener, Chuck
PUB. DATE
July 2004
SOURCE
Airman;Jul2004, Vol. 48 Issue 7, p50
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Presents an author's account regarding a soldier experiences in battling testicular cancer. Spread of cancer cells to other body parts; Treatment undergone; Lifestyle change after the disease.
ACCESSION #
13855136

 

Related Articles

  • THERAPEUTIC APPROACH IN BRAIN METASTASES. Vitan, Codruţa Marina; Moga, A.; Pereanu, M. // Acta Medica Transilvanica;mar2012, Vol. 17 Issue 1, p263 

    Brain metastases are the most feared complication of generalized malignancy and the most frequent intracranial tumour in adults. Brain metastases are a difficult problem of diagnosis and therapeutic management for the physician, while for the patient, it represents an emotional and physically...

  • Krukenberg Tumors from Colorectal Cancer: Presentation, Treatment and Outcomes. OJO, JOHN; DE SILVA, SADIE; HAN, ERNEST; LIN, PAUL; WAKABAYASHI, MARK; NELSON, REBECCA; LAI, LILY L. // American Surgeon;Oct2011, Vol. 77 Issue 10, p1381 

    Ovarian metastases from colorectal cancer (CRC), also known as Krukenberg Tumors (KT), occur in about 3 per cent of all colorectal cancer patients and make up between 5 to 10 per cent of all colorectal metastases. We sought to determine the effects of presentation of KT on treatment patterns and...

  • Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer. Miller, K; Moul, J W; Gleave, M; Fizazi, K; Nelson, J B; Morris, T; Nathan, F E; McIntosh, S; Pemberton, K; Higano, C S // Prostate Cancer & Prostatic Diseases;Jun2013, Vol. 16 Issue 2, p187 

    Background:Standard treatment options are limited for the management of non-metastatic castration-resistant prostate cancer (CRPC). This study, part of the ENTHUSE (EndoTHelin A USE) phase III programme, evaluated the efficacy and safety of the oral specific endothelin (ET)A receptor antagonist...

  • Optical quantification of cellular mass, volume, and density of circulating tumor cells identified in an ovarian cancer patient. Phillips, Kevin G.; Velasco, Carmen Ruiz; Julia Li; Kolatkar, Anand; Luttgen, Madelyn; Bethel, Kelly; Duggan, Bridgette; Kuhn, Peter; McCarty, Owen J. T. // Frontiers in Oncology;Jul2012, Vol. 2, p1 

    Clinical studies have demonstrated that circulating tumor cells (CTCs) are present in the blood of cancer patients with known metastatic disease across the major types of epithelial malignancies. Recent studies have shown that the concentration of CTCs in the blood is prognostic of overall...

  • The Multifaceted Manifestations of Cardiac Tumors. Buja, L. Maximilian // Texas Heart Institute Journal;2012, Vol. 39 Issue 1, p84 

    The author discusses a case report and series review of matastatic colon cancer involving the right atrium. The report focused on the occurrence of metastatic mucinous colonic carcinoma involving the right atrium and producing superior vena cava (SVC) syndrome and tumor emboli to the lungs and...

  • New experimental markers for early detection of high-risk prostate cancer: role of cell–cell adhesion and cell migration. Mol, A.J.M.; Geldof, A.A.; Meijer, G.A.; Poel, H.G.; Moorselaar, R.J. A. // Journal of Cancer Research & Clinical Oncology;Oct2007, Vol. 133 Issue 10, p687 

    Today’s treatment and diagnosis of prostate cancer still exhibit major limitations. The search for new and additional prognostic markers is therefore still an actual field of interest. Potential markers involved in numerous biological processes in the tumor cell have been investigated...

  • Lost in migration. Mack, George S.; Marshall, Andrew // Nature Biotechnology;Mar2010, Vol. 28 Issue 3, p214 

    The article examines the potential of the processes underlying metastasis to provide therapeutic options to cancers. Recent research found that tumor cells disseminate throughout the body. Another key clinical observation is the tendency of some cancers to metastasize soon after the progress of...

  • P-0273 STILL AWAITING THAT WAITING BE A VALIDATED AFFORDABLE OPTION IN RECTAL CANCER? OUR WATCH AND WAIT APPROACH EXPERIENCE IN CO-RECTO. Soledad, Iseas; Marcela, Carballido; Mariana, Coraglio; Fabio, Leiro; Adriana, Dieguez; Martin, Eleta; Guillermo, Mendez; Ariel, Aguilo; Mario, Barugel; Enrique, Roca // Annals of Oncology;Jun2014, Vol. 25 Issue suppl_2, pii99 

    No abstract available.

  • Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer. Bendell, Johanna; Rosen, Lee; Mayer, Robert; Goldman, Jonathan; Infante, Jeffrey; Benedetti, Fabio; Lin, Donghu; Mizuguchi, Hirokazu; Zergebel, Christopher; Patel, Manish; Bendell, Johanna C; Rosen, Lee S; Mayer, Robert J; Goldman, Jonathan W; Infante, Jeffrey R; Patel, Manish R // Cancer Chemotherapy & Pharmacology;Feb2016, Vol. 77 Issue 2, p439 

    No abstract available.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics